1372540-33-4

Basic information

• Product Name: 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxamide
• Synonyms: 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxamide
• CAS NO: 1372540-33-4
• Molecular Weight: 432.445
• Mol File: 1372540-33-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxamide(1372540-33-4)
• EPA Substance Registry System: 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxamide(1372540-33-4)

Safety Data

• Hazardous Substances Data: 1372540-33-4(Hazardous Substances Data)

Upstream product

• 1372540-34-5 C₂₂H₂₁ClF₃N₃O₂ 
• 1372540-21-0 methyl 2-methyl-5-(4-morpholinyl)-1H-benzimidazole-7-carboxylate 
• 1203486-58-1 methyl 3-amino-5-(4-morpholinyl)-2-nitrobenzoate 
• 874301-23-2 3-amino-5-chloro-2-nitrobenzoic acid methyl ester 
• 193481-78-6 3-Amino-5-chloro-2-nitrobenzoic acid 
• 2516-95-2 5-chloro-2-nitrobenzoic acid 
• 1372540-25-4 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(morpholin-4-yl)-1H-1,3-benzodiazole-4-carboxylic acid 
• 1372540-24-3 methyl 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylate 

Downstream Products

• 1372540-32-3 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-4-(4H-1,2,4-triazol-3-yl)-1H-benzimidazole 

Relevant articles and documents

BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS

This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ OH kinase family (hereinafter PI3 kinases), suitably, PI3Kα, PI3Kβ, PI3Kβ, and/or PI3Kγ. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3Kβ selective benzimidazoles compounds for treating cancer.